123,679 Shares in Janux Therapeutics, Inc. $JANX Purchased by Nuveen LLC

Key Points

• Nuveen LLC has acquired 123,679 shares of Janux Therapeutics, Inc. for approximately $3.3 million, bringing their total ownership to 0.21% of the company.
• Recent hedge fund activity shows significant increases in holdings for several investors, including RA Capital Management and Wellington Management Group, indicating strong institutional interest in Janux Therapeutics.
• Wall Street analysts are optimistic about Janux Therapeutics, with an average rating of "Buy" and a consensus target price of $86.90, reflecting a potential for significant stock appreciation.

Nuveen LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 123,679 shares of the company's stock, valued at approximately $3,339,000. Nuveen LLC owned 0.21% of Janux Therapeutics at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. RA Capital Management L.P. increased its position in shares of Janux Therapeutics by 13.1% during the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after acquiring an additional 1,200,000 shares during the period. Janus Henderson Group PLC increased its position in shares of Janux Therapeutics by 41.2% during the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after acquiring an additional 1,038,996 shares during the period. Paradigm Biocapital Advisors LP increased its position in shares of Janux Therapeutics by 46.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after acquiring an additional 1,115,412 shares during the period. Vanguard Group Inc. increased its position in shares of Janux Therapeutics by 6.7% during the first quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock worth $61,524,000 after acquiring an additional 142,328 shares during the period. Finally, Woodline Partners LP increased its position in shares of Janux Therapeutics by 15.7% during the fourth quarter. Woodline Partners LP now owns 1,852,187 shares of the company's stock worth $99,166,000 after acquiring an additional 251,924 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Up 0.6%

Shares of NASDAQ JANX traded up $0.14 during midday trading on Tuesday, reaching $22.86. 904,571 shares of the company were exchanged, compared to its average volume of 787,388. Janux Therapeutics, Inc. has a 1 year low of $21.97 and a 1 year high of $71.71. The stock has a fifty day simple moving average of $24.50 and a 200 day simple moving average of $26.96. The stock has a market cap of $1.37 billion, a P/E ratio of -12.70 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on JANX. Piper Sandler assumed coverage on Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 price objective on the stock. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.